Slide 1: Oriola Corporation Q4 2022 & FY 2022 results
Oriola Corporation Q4 2022 & FY 2022 results
Slide 2: Disclaimer
Disclaimer The following applies to this presentation, the oral presentation of the information in this presentation by Oriola Corporation (the “Company” or “Oriola”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the “In
Slide 3: Agenda
Agenda • Q4 2022 overview • Operating environment • Financials and Outlook for 2023 • Key takeaways and priorities 2023 16.2.2023 3
Slide 4: Q4 2022 key points
Q4 2022 key points • Demand continued on good level, profit weakened by impairments • Net sales -3.1% and invoicing -3.8%. At constant currencies, net sales +1.9% and invoicing +1.1% • Adjusted EBIT decreased to EUR 0.9m (6.6) • Loss of public tenders and consequently patients in the dose dispensing
Slide 5: Sustainability highlights
Sustainability highlights CDP Oriola received a recognition for its environmental work by achieving CDP’s best leadership level with score A- (scale of A-D). Oriola's scoring exceeded average scoring in its benchmark group. ENVIRONMENTAL PERFORMANCE Electricity and heat consumption in own operations
Slide 6: Dividend proposal
Dividend proposal EUR Dividend payout 0,1 0.09 0.09 0,08 The Board of Directors proposes to 0.06 0.06 0.06 0.06 the AGM that a dividend of EUR 0.06 0,06 0.04 0.04 per share be paid for 2022. 0,04 0.03 Record date: 23 March 0,02 Payment date: 14 April 0 2018 2019 2020 2021 2022 -0,02 -0.01 EPS DPS Di
Slide 7: Operating environment and markets
Operating environment and markets
Slide 8: Operating environment
Operating environment • Overall good market demand continued in Sweden and Finland • Increased economic uncertainty did not impact the pharmaceutical market, albeit growth slowed somewhat in Finland in Q4 • Tighter raw material supply for medical products, impacting the availability of some pharmace
Slide 9: Pharmaceutical wholesale markets were growing in Q4
Pharmaceutical wholesale markets were growing in Q4 Market share pharmaceutical wholesale Market share dose dispensing Sweden Sweden Pharmaceutical market in value Q4: Total market 54 BSEK Oriola 44% (46%) Oriola 30% (41%) Sweden +8.3% ~ 260,000 Others 56% (54%) patients Others 70% (59%) Source: IQV
Slide 10: Financials Q4 2022 and Outlook for 2023
Financials Q4 2022 and Outlook for 2023
Slide 11: Adjusted EBIT, Continuing operations
Adjusted EBIT, Continuing operations 2021-2022 Adj. EBIT and Adj. EBIT in constant currency EUR million 8 6,6 6,6 6,8 6 5.4 5.5 5.6 4,7 4,8 4 2,0 2 0,9 0,9 0,9 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2021 2021 2021 2021 2022 2022 2022 2022 Adj. EBIT Adj. EBIT in constant currency 16.2.2023 11
Slide 12: Profit and EPS decreased, burdened by impairments
Profit and EPS decreased, burdened by impairments* Profit for the period, continuing operations Earnings per share, continuing operations EUR million EUR 2020 2021 2022 2022 Excl. impairment 2020 2021 2022 2022 Excl. impairment 10 0.08 0.06 5,5 5,3 5 4.3 3.8 0.04 0.03 0.03 2,1 1,5 0,02 0,02 1,3 0,7
Slide 13: Strong year-to-date cash flow
Strong year-to-date cash flow Quarterly net cash flow from operating activities1 Q4 YTD 2022 change in cash1 EUR million EUR million 2020 2021 2022 80 200 3,0 60 46 42 150 77,9 -29.4 39 36 40 29 28 20 100 9 4 160,6 0 0 50 109,1 -20 -14 -16 -26 -40 0 Q1 Q2 Q3 Q4 Cash Operating Investing Financing Cas
Slide 14: Net debt declined Y/Y due to pharmacy business combination and strong cash flow
Net debt declined Y/Y due to pharmacy business combination and strong cash flow Net interest-bearing debt1 Net interest-bearing debt items EUR million EUR million 2020 2021 2022 160 Net interest-bearing debt item 31 Dec 2022 31 Dec 20211 Bank loans 61.1 65.3 120 (syndicated Bank & term) Commercial p
Slide 15: Swedish Pharmacy Holding in Q4 2022
Swedish Pharmacy Holding in Q4 2022 • Net sales EUR 293m • Adjusted EBIT EUR -2.8m • Realised synergies EUR 1.0m • Adjusting items EUR 1.9m • EBITA EUR -1.3m • Net debt EUR 95.3m Oriola booked a loss of EUR 2.0m in Q4 2022 from Swedish Pharmacy Holding AB. Oriola is committed to long-term ownership.
Slide 16: Outlook for 2023
Outlook for 2023 Oriola expects the adjusted EBIT, excluding the contribution from the joint venture Swedish Pharmacy Holding AB, to remain on the same level compared to 2022. The outlook takes into consideration the significant negative impact on Oriola’s profitability from the loss of public tende
Slide 17: Key takeaways and priorities 2023
Key takeaways and priorities 2023
Slide 18: Q4 2022 Key takeaways
Q4 2022 Key takeaways Invoicing and net sales rose at constant currencies - 1 Continued good market demand. Higher input costs such as transportation, partly offset by 2 savings from turnaround initiatives. Turnaround activities completed as planned – improved 3 efficiency, good product pricing and
Slide 19: Our key priorities 2023
Our key priorities 2023 Profitable Efficiency Culture Growth Enhance value Increase operational creation through a Drive profitable growth and capital efficiency collaborative culture The preferred business partner in the Nordics Sustainability at the core The forerunner in the advanced distribution
Slide 20: Our next events / Thank you!
Our next events 21/3/2023 Annual General Meeting 2023 27/4/2023 Q1/2023 interim report Contact: investor.relations@oriola.com Thank you!
Slide 21: 16.2.2023
16.2.2023 21